<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155212449030</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155212449030</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeted therapy for gastric cancer—current status</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kulig</surname><given-names>Jan</given-names></name>
</contrib>
<aff id="aff1-1078155212449030">Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, Krakow, Poland</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kołodziejczyk</surname><given-names>Piotr</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155212449030"/>
</contrib>
<aff id="aff2-1078155212449030">Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, Krakow, Poland</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kulig</surname><given-names>Piotr</given-names></name>
</contrib>
<aff id="aff3-1078155212449030">Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, Krakow, Poland</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Legutko</surname><given-names>Janusz</given-names></name>
</contrib>
<aff id="aff4-1078155212449030">Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, Krakow, Poland</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155212449030">Piotr Kołodziejczyk, Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, 40 Kopernika Street, 31-501 Krakow, Poland. Email: <email>p.kolo@interia.p</email>l</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>75</fpage>
<lpage>81</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>In patients with metastatic gastric cancer, median overall survival remains under 1 year and standard chemotherapy regimens are not able to substantially improve the prognosis of the patients. Amplification and over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. There are several targeted therapies in different stages of clinical development with trastuzumab being the first overcoming the regulatory hurdle and getting European Medicines Agency approval. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events. Other agents targeting the HER2 pathway (lapatinib) or other domains of epidermal growth factor receptor family (cetuximab) are currently being investigated for the treatment of an advanced gastric cancer.</p>
</abstract>
<kwd-group>
<kwd>Gastric cancer</kwd>
<kwd>HER2 over-expression</kwd>
<kwd>HER2 amplification</kwd>
<kwd>targeted treatment</kwd>
<kwd>trastuzumab</kwd>
<kwd>lapatinib</kwd>
<kwd>cetuximab</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155212449030" sec-type="intro"><title>Introduction</title>
<p>Gastric cancer is a frequent malignancy representing 7.8% of all cancers.<sup><xref ref-type="bibr" rid="bibr1-1078155212449030">1</xref></sup> Although the incidence of gastric cancer is decreasing, there were still 159,900 new cases in Europe in 2006, and approximately 118,200 deaths, representing the fifth highest incidence and fourth highest cause of cancer-related death.<sup><xref ref-type="bibr" rid="bibr2-1078155212449030">2</xref></sup></p>
<p>Risk factors for gastric cancer include <italic>Helicobacter pylori</italic> infection, smoking, low socioeconomic status, high alcohol consumption intake of salty foods, low consumption of vegetables and fruits, male sex, obesity and gastrointestinal reflux.<sup><xref ref-type="bibr" rid="bibr3-1078155212449030">3</xref></sup></p>
<p>It is often diagnosed at an advanced stage with approximately half of patients presenting an unresectable locally advanced or metastatic disease. Based on current evidence, 5-year survival for advanced or metastatic gastric cancer is around 5–20%, with median overall survival being less than 1 year. Nearly half of the patients respond to chemotherapy triplets containing cisplatin (CF), fluorouracil (FU) and anthracyclines or taxanes. Unfortunately, median survival remains under 12 months even with the most active combinations.<sup><xref ref-type="bibr" rid="bibr4-1078155212449030">4</xref></sup></p>
<p>There is growing evidence that biomarker HER2 is a key driver of tumourigenesis in gastric cancer. Clinical studies have shown amplification or over-expression in 7–34% of tumours. There is also some evidence that HER2-positive status in gastric cancer is associated with poor outcomes and aggressive disease.<sup><xref ref-type="bibr" rid="bibr5-1078155212449030">5</xref>,<xref ref-type="bibr" rid="bibr6-1078155212449030">6</xref></sup></p>
</sec>
<sec id="sec2-1078155212449030"><title>Limitations of conventional chemotherapy</title>
<p>The only currative approach in gastric cancer remains the complete resection of the primary tumour and adjacent lymph nodes with approximately 5-year survival for stage I 60–90% and for stage II 30–50%.<sup><xref ref-type="bibr" rid="bibr7-1078155212449030">7</xref></sup> Chemotherapy in either adjuvant or metastatic setting is counting only small survival benefit for patients with gastric cancer.</p>
<p>Several clinical trials in patients with perioperative chemotherapy for resectable gastric cancer were utilizing different treatment schedules. The overall survival benefit has been shown for FU/leucovorin versus surgery alone<sup><xref ref-type="bibr" rid="bibr8-1078155212449030">8</xref></sup> and for epirubicin, CF and 5-fluorouracil combination.<sup><xref ref-type="bibr" rid="bibr9-1078155212449030">9</xref></sup></p>
<p>Many chemotherapy agents have been studied either as single treatments or combination regimens in patients with advanced gastric cancer with inconclusive results and only modest treatment effect. Despite some objective response rates, the median overall survival rates remain lower than 1 year.<sup><xref ref-type="bibr" rid="bibr4-1078155212449030">4</xref>,<xref ref-type="bibr" rid="bibr10-1078155212449030">10</xref></sup> The clinical activity and modest overall survival prolongation has been demonstrated for combinations of 5-fluorouracil, epirubicin and CF.<sup><xref ref-type="bibr" rid="bibr11-1078155212449030">11</xref></sup> Other combinations, including etoposide, leucovorin and FU (ELF), infusional FU plus CF and etoposide, epirubicin and cisplatin (EEC) have not proven survival benefit.<sup><xref ref-type="bibr" rid="bibr12-1078155212449030">12</xref>,<xref ref-type="bibr" rid="bibr13-1078155212449030">13</xref></sup> Taxanes (either docetaxel or paclitaxel) has been tested in advanced gastric cancer with mixed results in first and further lines of treatment.<sup><xref ref-type="bibr" rid="bibr14-1078155212449030">14</xref>,<xref ref-type="bibr" rid="bibr15-1078155212449030">15</xref></sup> From more recent antitumour agents, oxaliplatin, irinotecan and oxaliplatin have been used. Oxaliplatin did not reveal any significant advantage over CF-based regimens.<sup><xref ref-type="bibr" rid="bibr16-1078155212449030">16</xref></sup> Either irinotecan has not been more successful in comparison with docetaxel<sup><xref ref-type="bibr" rid="bibr17-1078155212449030">17</xref></sup> or CF.<sup><xref ref-type="bibr" rid="bibr18-1078155212449030">18</xref></sup></p>
<p>In recent Cochrane systematic review, 35 trials with a total number of 5726 patients have been analysed.<sup><xref ref-type="bibr" rid="bibr19-1078155212449030">19</xref></sup> The comparison of chemotherapy versus best supportive care consistently demonstrated a significant benefit in overall survival in favour of the group receiving chemotherapy (hazard ratios (HR) 0.37; 95% confidence intervals (CI) 0.24 to 0.55, 184 participants). The comparison of combination versus single-agent chemotherapy provides evidence for a survival benefit in favour of combination chemotherapy (HR 0.82; 95% CI 0.74 to 0.90, 1914 participants). The price of this benefit is increased toxicity as a result of combination chemotherapy. When comparing FU/CF-containing combination therapy regimens versus without anthracyclines (HR 0.77; 95% CI 0.62 to 0.95, 501 participants) and FU/anthracycline-containing combinations versus without CF (HR 0.82; 95%CI 0.73 to 0.92, 1147 participants), there was a significant survival benefit for regimens including FU, anthracyclines and CF. Both the comparison of irinotecan versus non-irinotecan (HR 0.86; 95% CI 0.73 to 1.02, 639 participants) and docetaxel versus non-docetaxel containing regimens (HR 0.93; 95% CI 0.75 to 1.15, 805 participants) show non-significant overall survival benefits in favour of the irinotecan and docetaxel-containing regimens.</p>
</sec>
<sec id="sec3-1078155212449030"><title>HER2 expression</title>
<p>Over-expression and amplifications of HER2 have been found in several types of malignances. Most of the findings are coming from breast cancer patients. This finding was reported for gastric, ovarian, prostate, pancreatic and colorectal cancers.<sup><xref ref-type="bibr" rid="bibr20-1078155212449030">20</xref><xref ref-type="bibr" rid="bibr21-1078155212449030"/>–<xref ref-type="bibr" rid="bibr22-1078155212449030">22</xref></sup> There are several methods available for the detection of HER2 protein over-expression (immunohistochemistry (IHC)) or <italic>HER2</italic> gene amplification (fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization).<sup><xref ref-type="bibr" rid="bibr23-1078155212449030">23</xref></sup></p>
<p>In breast cancer, HER2 status is key predictive biomarker for treatment with HER2 inhibitors such as the monoclonal antibody trastuzumab (Herceptin, Roche) and tyrosine kinase inhibitor lapatinib (Tyverb/Tykerb, GSK). HER2 is a member of the HER family of tyrosine kinases that are involved in tumour proliferation, apoptosis, adhesion, migration and differentiation, and antibody-dependent cytotoxicity.<sup><xref ref-type="bibr" rid="bibr24-1078155212449030">24</xref></sup></p>
<p>There are many clinical studies confirming the over-expression of HER2 protein or amplification of <italic>HER2</italic> gene in gastric cancer with high variation in number of patients with HER2-positive tumours (range 8.2% to 53.4%; see Jorgensen 2010 for review<sup><xref ref-type="bibr" rid="bibr25-1078155212449030">25</xref></sup>). The authors have weighted the results from 24 studies reviewed with the final number of 19% with HER2-positive gastric cancers.<sup><xref ref-type="bibr" rid="bibr25-1078155212449030">25</xref></sup></p>
<p>In the recently published Trastuzumab for Gastric Cancer trial (ToGA) tumours from 3807 patients were centrally tested for HER2 status both as <italic>HER2</italic> gene amplification and HER2 protein over-expression.<sup><xref ref-type="bibr" rid="bibr26-1078155212449030">26</xref></sup> The results have identified 22.1% of patients with advanced gastric cancer as HER2-positive either by FISH or IHC. The number of HER2-positive patients was shown to be higher in the localization of cancer close to the gastro-oesophageal junction in comparison with stomach.<sup><xref ref-type="bibr" rid="bibr27-1078155212449030">27</xref></sup></p>
<p>In generalized gastric cancer, the prognostic value of HER2 positivity remains questionable. The validation of the general prognostic significance of <italic>HER2</italic> gene amplification and protein over-expression in the absence of anti-HER2-targeted therapy in breast cancer patients has been evaluated in 107 published studies involving 39,730 patients, which produced an overall HER2-positive rate of 22.2% and a mean relative risk for overall survival (OS) of 2.74.<sup><xref ref-type="bibr" rid="bibr23-1078155212449030">23</xref></sup></p>
<p>Recently, Cidon et al. published retrospective review of 120 cases. Overall expression has been detected in 7.5%. Early recurrences were higher inHER2-positive (66.6% vs. 35.4%, <italic>p = </italic>0<italic>.</italic>048). The median disease-free survival (DFS) for c-erbB-2 positive was 15 months (range 2–67 months), and OS was 25 months (range 10–67 months). In the case of patients with c-erbB-2, negative median DFS was 27 months (range 5–67 months) and OS for this sample is 47 months (range 29–67 months).<sup><xref ref-type="bibr" rid="bibr28-1078155212449030">28</xref></sup> Liu et al. has shown that intestinal-type and early-stage cancers with HER2/neu over-expression exhibited short 5-year survival rates (21% vs. 47%, <italic>p</italic> = 0.027; 29% vs. 60%, <italic>p</italic> = 0.037) than HER2/neu-negative cases.<sup><xref ref-type="bibr" rid="bibr29-1078155212449030">29</xref></sup></p>
<p>The first evidence of antitumour effect of HER2 inhibition came from preclinical in vitro and in vivo studies using of HER2-specific antibodies.<sup><xref ref-type="bibr" rid="bibr30-1078155212449030">30</xref></sup> In the second step, these studies have been successfully repeated wit trastuzumab and lapatinib using the different tumour cell lines. Trastuzumab has been used in preclinical models as monotherapy and in drug-drug combinations with chemotherapy (CF, irinotecan, paclitaxel, FU, capecitabine).<sup><xref ref-type="bibr" rid="bibr31-1078155212449030">31</xref>,<xref ref-type="bibr" rid="bibr32-1078155212449030">32</xref></sup></p>
</sec>
<sec id="sec4-1078155212449030"><title>Targeted treatments</title>
<p>The deeper understanding of carcinogenesis on molecular level has stimulated research and development of rationally designed anticancer drugs that target specific pathways of cancer cell growth. There are several targeted therapies on the basis of monoclonal antibodies in different stages of clinical development and first of them has reached the successful regulatory approval. These innovative treatments have several mechanisms of actions. One group is affecting the epidermal growth factor receptor (EGFR) family including HER2 protein and another is targeting vascular endothelial growth factor (VEGF).</p>
<p>The first targeted drug successfully overcoming the regulatory hurdle is trastuzumab.<sup><xref ref-type="bibr" rid="bibr26-1078155212449030">26</xref></sup> Other agents that target the HER2 pathway are currently being investigated for the treatment of advanced gastric cancer. One such drug is lapatinib, a reversible tyrosine kinase inhibitor that targets the tyrosine kinase domain of the HER2 receptor, resulting in inhibition of HER2 receptor signaling.<sup><xref ref-type="bibr" rid="bibr33-1078155212449030">33</xref></sup> Other approaches include cetuximab as high-affinity EGFR antibody<sup><xref ref-type="bibr" rid="bibr34-1078155212449030">34</xref></sup> or bevacizumab, a humanized monoclonal antibody against VEGF.<sup><xref ref-type="bibr" rid="bibr35-1078155212449030">35</xref></sup></p>
</sec>
<sec id="sec5-1078155212449030"><title>Trastuzumab</title>
<p>Trastuzumab is a recombinant humanized IgG1k monoclonal antibody designed to target and block the function of HER2 protein.<sup><xref ref-type="bibr" rid="bibr36-1078155212449030">36</xref></sup> It has been utilized for the treatment of HER2-over-expressing breast cancer for more than 10 years.<sup><xref ref-type="bibr" rid="bibr37-1078155212449030">37</xref></sup> In January 2010, trastuzumab was approved by the European Medicines Agency (EMA) for use in combination with capecitabine or 5 FU and CF for metastatic gastric or gastro-oesophageal junction cancer. It has been proven that trastuzumab is unlikely to elicit a human antimouse antibody response and therefore possesses low immunogenicity. Binding of trastuzumab leads to inhibition of HER2-mediated downstream signaling and prevents formation of p95HER2, a truncated and constitutively active HER2 variant derived from cleavage of the extracellular domain of the receptor.<sup><xref ref-type="bibr" rid="bibr38-1078155212449030">38</xref></sup></p>
<p>The over-expression of HER2 occurs in 20–25% of breast cancers and is associated with aggressive disease and poor prognosis. Trastuzumab has been approved for use in adjuvant setting for HER2-positive and node-positive breast cancer in combination with chemotherapy.<sup><xref ref-type="bibr" rid="bibr39-1078155212449030">39</xref>,<xref ref-type="bibr" rid="bibr40-1078155212449030">40</xref></sup> Trastuzumab has also been proven to be effective in metastatic breast cancer when used as first-, second- or third-line monotherapy, and when used as first-line therapy in combination with chemotherapy.<sup><xref ref-type="bibr" rid="bibr41-1078155212449030">41</xref>,<xref ref-type="bibr" rid="bibr42-1078155212449030">42</xref></sup></p>
<p>The positive results have been achieved in phase II trial in HER2-positive advanced gastric or gastro-oesophageal junction cancer. Treatment consisted of trastuzumab (8 mg/kg on cycle 1 day 1 as loading; 6 mg/kg in subsequent cycles) and CF (75 mg/m(2)), both intravenously on day 1, every 21 days. The disease control was achieved in 64% of patients and median time to progression was 5.1 months.<sup><xref ref-type="bibr" rid="bibr43-1078155212449030">43</xref></sup></p>
<p>The objective of the ToGA study was to assess the clinical efficacy and safety of trastuzumab added to chemotherapy for first-line treatment of advanced gastric or gastro-oesophageal junction cancers with over-expression of HER2.<sup><xref ref-type="bibr" rid="bibr26-1078155212449030">26</xref></sup> The median follow-up for all the patients in the trial was reported to be 17.1 months. The 594 HER2-positive patients were randomised to receive either chemotherapy alone (capecitabine and CF or FU and CF) or chemotherapy in combination with trastuzumab. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. The median overall survival increased from 11.1 to 13.5 months (<italic>p</italic> = 0.0048) with a hazard ratio of 0.74 (95% CI 0.60–0.91).</p>
<p>Furthermore, an exploratory, post-hoc analysis showed that trastuzumab plus chemotherapy substantially improved overall survival in patients with high expression of HER2 protein (IHC 2+ and FISH positive or IHC 3+) compared with patients with low expression of HER2 protein (IHC 0 or 1+ and FISH positive). A total of 446 patients fulfilled these criteria and the overall survival for this subpopulation has increased to 16.0 months compared to 11.8 months in the chemotherapy alone group.<sup><xref ref-type="bibr" rid="bibr26-1078155212449030">26</xref></sup></p>
<p>The ToGA trial is the first positive phase III clinical trial investigating targeted therapies in advanced gastric cancer in combination with platinum-based chemotherapy with one additional safety benefit. Adverse events profile did not differ significantly between the groups either for all grades or for grades 3 and 4.<sup><xref ref-type="bibr" rid="bibr26-1078155212449030">26</xref></sup> Nausea, neutropenia, vomiting and anorexia were the most frequently reposted adverse events. Additionally, rates of cardiac adverse events were low in this trial in patients with advanced gastric cancer (including low rates of cardiac failure). The negligible number of patients previously exposed to anthracyclines, which are known to be toxic to myocytes, might have affected these results.</p>
</sec>
<sec id="sec6-1078155212449030"><title>Lapatinib</title>
<p>Lapatinib is a potent competitive inhibitor of the HER2/neu and EGFR tyrosine kinase domains. It has demonstrated efficacy in patients with tumours over-expressing either EGFR or HER2. Currently lapatinib is approved in the HER2-positive metastatic breast cancer patients in combination with capecitabine after progression with trastuzumab, anthracycline and taxane.<sup><xref ref-type="bibr" rid="bibr33-1078155212449030">33</xref></sup> There is preclinical and early clinical evidence showing that lapatinib is inhibiting growth of HER2-positive gastric cancer cell lines with synergistic effect together with conventional chemotherapy.<sup><xref ref-type="bibr" rid="bibr44-1078155212449030">44</xref>,<xref ref-type="bibr" rid="bibr45-1078155212449030">45</xref></sup> Cell cycle analysis revealed that lapatinib induced G(1) arrest in sensitive lines.<sup><xref ref-type="bibr" rid="bibr46-1078155212449030">46</xref></sup> Presently ongoing is the phase III clinical trial in patients with advanced gastric cancer where lapatinib is added to capecitabine plus oxaliplatin. It will be interesting to see whether the dual action of the drug will provide additional benefits over trastuzumab, especially considering that EGFR also seems to be over-expressed in patients with gastric cancer.</p>
</sec>
<sec id="sec7-1078155212449030"><title>Cetuximab</title>
<p>Cetuximab is high-affinity chimeric mouse human antibody to extracellular portion of EGFR. Cetiximab is today approved for the treatment of metastatic colon cancer.<sup><xref ref-type="bibr" rid="bibr47-1078155212449030">47</xref></sup> In gastric cancer, EGFR over-expression has been reported in 20 to 80% of tumours and there is a correlation with more advanced tumours, metastatic disease and poorer prognosis.<sup><xref ref-type="bibr" rid="bibr48-1078155212449030">48</xref>,<xref ref-type="bibr" rid="bibr49-1078155212449030">49</xref></sup> In clinical trials with gastric cancer patients, it has been investigated in combination with conventional chemotherapy in several phase II trials. Cetuximab was added to combination with carboplatin and paclitaxel with concurrent radiation. The complete remission rates have achieved 70% but survival data were not reported.<sup><xref ref-type="bibr" rid="bibr50-1078155212449030">50</xref></sup> More positive results have been obtained in combination with docetaxel and oxaliplatin, but the cetuximab treatment was accompanied with high incidence of severe skin reactions.<sup><xref ref-type="bibr" rid="bibr51-1078155212449030">51</xref>,<xref ref-type="bibr" rid="bibr52-1078155212449030">52</xref></sup> High disease control rate (79%) has been achieved also in combination with irinotecan/folinic acid/FU.<sup><xref ref-type="bibr" rid="bibr53-1078155212449030">53</xref></sup> Contrary cetuximab administered as a single agent had minimal clinical activity in patients with metastatic oesophageal and gastric adenocarcinoma.<sup><xref ref-type="bibr" rid="bibr54-1078155212449030">54</xref></sup> However, the results from confirmative phase III trial are still awaited.</p>
</sec>
<sec id="sec8-1078155212449030"><title>Other agents</title>
<p>Recently published phase III AVAGAST trial with bevacizumab did not reach its primary objective in median overall survival parameter. Adding bevacizumab to chemotherapy (CF, capecitabine) was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.<sup><xref ref-type="bibr" rid="bibr55-1078155212449030">55</xref></sup> The promising data are comming from phase II trial with bevacizumab plus docetaxel and oxaliplatin where stable disease has been observed in 37% and complete/partial responses in 42% of patients.<sup><xref ref-type="bibr" rid="bibr56-1078155212449030">56</xref></sup> Erlotnib plus modified FOLFOX6 regimen (oxaliplatin 85 mg m(-2), FU 400 mg m(-2), LV 400 mg m(-2) on day 1, FU 2400 mg m(-2) over 48 h) has been tested in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Median progression-free survival (PFS) was 5.5 months and median overall survival was 11.0 months.<sup><xref ref-type="bibr" rid="bibr57-1078155212449030">57</xref></sup> The median progression-free survival was 5.8 months and the median overall survival was 13.6 months for combination of sorafenib with docetaxel and CF in phase II trial.<sup><xref ref-type="bibr" rid="bibr58-1078155212449030">58</xref></sup> All these promising results are awaiting confirmation in controlled phase III trials.</p>
</sec>
<sec id="sec9-1078155212449030"><title>Conclusions and future directions</title>
<p>Targeted agents will have an increasingly important role in the treatment of patients with gastric cancer. The results from the ToGA trial are a major step forward in the treatment of advanced gastric cancer and it is likely that trastuzumab will next be evaluated for efficacy in the adjuvant setting. We can expect many successors from the family of monoclonal antibodies targeting HER2, EGFR or VEGFR. Although numerous phase I and II studies have shown promising results, the confirmation from large comparative pivotal trials, like ToGA trial, are still not available.</p>
</sec>
</body>
<back>
<sec id="sec10-1078155212449030"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1078155212449030"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>HR</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title>. <source>Int J Cancer</source> <year>2010</year>; <volume>127</volume>(<issue>12</issue>): <fpage>2893</fpage>–<lpage>2917</lpage>.</citation></ref>
<ref id="bibr2-1078155212449030"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okines</surname><given-names>A</given-names></name><name><surname>Verheij</surname><given-names>M</given-names></name><name><surname>Allum</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <year>2010</year>; <volume>21</volume>: <supplement>Suppl. 5</supplement><fpage>v50</fpage>–<lpage>v54</lpage>.</citation></ref>
<ref id="bibr3-1078155212449030"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamangar</surname><given-names>F</given-names></name><name><surname>Dores</surname><given-names>GM</given-names></name><name><surname>Anderson</surname><given-names>WF</given-names></name></person-group>. <article-title>Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world</article-title>. <source>J Clin Oncol</source> <year>2006</year>; <volume>24</volume>(<issue>14</issue>): <fpage>2137</fpage>–<lpage>2150</lpage>.</citation></ref>
<ref id="bibr4-1078155212449030"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name></person-group>. <article-title>Multidisciplinary management of gastric cancer</article-title>. <source>Curr Opin Gastroenterol</source> <year>2010</year>; <volume>26</volume>(<issue>6</issue>): <fpage>640</fpage>–<lpage>646</lpage>.</citation></ref>
<ref id="bibr5-1078155212449030"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gravalos</surname><given-names>C</given-names></name><name><surname>Jimeno</surname><given-names>A</given-names></name></person-group>. <article-title>HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target</article-title>. <source>Ann Oncol</source> <year>2008</year>; <volume>19</volume>(<issue>9</issue>): <fpage>1523</fpage>–<lpage>1529</lpage>.</citation></ref>
<ref id="bibr6-1078155212449030"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Hollmen</surname><given-names>M</given-names></name><name><surname>Junttila</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>Amplification of HER-2 in gastric carcinoma: association with <italic>Topoisomerase IIalpha</italic> gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab</article-title>. <source>Ann Oncol</source> <year>2005</year>; <volume>16</volume>(<issue>2</issue>): <fpage>273</fpage>–<lpage>278</lpage>.</citation></ref>
<ref id="bibr7-1078155212449030"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name></person-group>. <article-title>Multidisciplinary management of gastric cancer</article-title>. <source>Curr Opin Gastroenterol</source> <year>2010</year>; <volume>26</volume>(<issue>6</issue>): <fpage>640</fpage>–<lpage>646</lpage>.</citation></ref>
<ref id="bibr8-1078155212449030"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Smalley</surname><given-names>SR</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction</article-title>. <source>N Engl J Med</source> <year>2001</year>; <volume>345</volume>(<issue>10</issue>): <fpage>725</fpage>–<lpage>730</lpage>.</citation></ref>
<ref id="bibr9-1078155212449030"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Allum</surname><given-names>WH</given-names></name><name><surname>Stenning</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr10-1078155212449030"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>SR</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name></person-group>. <article-title>Gastric cancer: epidemiology, pathology and treatment</article-title>. <source>Ann Oncol</source> <year>2003</year>; <volume>14</volume>: <supplement>Suppl 2</supplement><fpage>ii31</fpage>–<lpage>ii36</lpage>.</citation></ref>
<ref id="bibr11-1078155212449030"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>JS</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial</article-title>. <source>Br J Cancer</source> <year>1999</year>; <volume>80</volume>(<issue>1–2</issue>): <fpage>269</fpage>–<lpage>272</lpage>.</citation></ref>
<ref id="bibr12-1078155212449030"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Icli</surname><given-names>F</given-names></name><name><surname>Celik</surname><given-names>I</given-names></name><name><surname>Aykan</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group</article-title>. <source>Cancer</source> <year>1998</year>; <volume>83</volume>(<issue>12</issue>): <fpage>2475</fpage>–<lpage>2480</lpage>.</citation></ref>
<ref id="bibr13-1078155212449030"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group</article-title>. <source>J Clin Oncol</source> <year>2000</year>; <volume>18</volume>(<issue>14</issue>): <fpage>2648</fpage>–<lpage>2657</lpage>.</citation></ref>
<ref id="bibr14-1078155212449030"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>GS</given-names></name><name><surname>Lee</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer</article-title>. <source>Cancer Res Treat</source> <year>2008</year>; <volume>40</volume>(<issue>3</issue>): <fpage>106</fpage>–<lpage>110</lpage>.</citation></ref>
<ref id="bibr15-1078155212449030"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Sohn</surname><given-names>SK</given-names></name><name><surname>Chae</surname><given-names>YS</given-names></name><etal/></person-group>. <article-title>Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group</article-title>. <source>Br J Cancer</source> <year>2008</year>; <volume>98</volume>(<issue>3</issue>): <fpage>542</fpage>–<lpage>546</lpage>.</citation></ref>
<ref id="bibr16-1078155212449030"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Probst</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie</article-title>. <source>J Clin Oncol</source> <year>2008</year>; <volume>26</volume>(<issue>9</issue>): <fpage>1435</fpage>–<lpage>1442</lpage>.</citation></ref>
<ref id="bibr17-1078155212449030"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gubanski</surname><given-names>M</given-names></name><name><surname>Johnsson</surname><given-names>A</given-names></name><name><surname>Fernebro</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial</article-title>. <source>Gastric Cancer</source> <year>2010</year>; <volume>13</volume>(<issue>3</issue>): <fpage>155</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr18-1078155212449030"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dank</surname><given-names>M</given-names></name><name><surname>Zaluski</surname><given-names>J</given-names></name><name><surname>Barone</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction</article-title>. <source>Ann Oncol</source> <year>2008</year>; <volume>19</volume>(<issue>8</issue>): <fpage>1450</fpage>–<lpage>1457</lpage>.</citation></ref>
<ref id="bibr19-1078155212449030"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Unverzagt</surname><given-names>S</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Chemotherapy for advanced gastric cancer</article-title>. <source>Cochrane Database Syst Rev</source> <year>2010</year><issue>(3</issue><fpage>CD004064</fpage>–<lpage>CD004064</lpage>.</citation></ref>
<ref id="bibr20-1078155212449030"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Godolphin</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title>. <source>Science</source> <year>1989</year>; <volume>244</volume>(<issue>4905</issue>): <fpage>707</fpage>–<lpage>712</lpage>.</citation></ref>
<ref id="bibr21-1078155212449030"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Kelly</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>HER-2 prolining and targeting in prostate carcinoma</article-title>. <source>Cancer</source> <year>2002</year>; <volume>94</volume>(<issue>4</issue>): <fpage>980</fpage>–<lpage>986</lpage>.</citation></ref>
<ref id="bibr22-1078155212449030"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safran</surname><given-names>H</given-names></name><name><surname>Steinhoff</surname><given-names>M</given-names></name><name><surname>Mangray</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma</article-title>. <source>Am J Clin Oncol</source> <year>2001</year>; <volume>24</volume>(<issue>5</issue>): <fpage>496</fpage>–<lpage>499</lpage>.</citation></ref>
<ref id="bibr23-1078155212449030"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Slodkowska</surname><given-names>EA</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><etal/></person-group>. <article-title>The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine</article-title>. <source>Oncologist</source> <year>2009</year>; <volume>14</volume>(<issue>4</issue>): <fpage>320</fpage>–<lpage>368</lpage>.</citation></ref>
<ref id="bibr24-1078155212449030"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hudis</surname><given-names>CA</given-names></name></person-group>. <article-title>Trastuzumab: mechanism of action and use in clinical practice</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>(<issue>1</issue>): <fpage>39</fpage>–<lpage>51</lpage>.</citation></ref>
<ref id="bibr25-1078155212449030"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>JT</given-names></name></person-group>. <article-title>Targeted HER2 treatment in advanced gastric cancer</article-title>. <source>Oncology</source> <year>2010</year>; <volume>78</volume>(<issue>1</issue>): <fpage>26</fpage>–<lpage>33</lpage>.</citation></ref>
<ref id="bibr26-1078155212449030"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Feyereislova</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title>. <source>Lancet</source> <year>2010</year>; <volume>376</volume>(<issue>9742</issue>): <fpage>687</fpage>–<lpage>697</lpage>.</citation></ref>
<ref id="bibr27-1078155212449030"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Hollmén</surname><given-names>M</given-names></name><name><surname>Junttila</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab</article-title>. <source>Ann Oncol</source> <year>2005</year>; <volume>16</volume>(<issue>2</issue>): <fpage>273</fpage>–<lpage>278</lpage>.</citation></ref>
<ref id="bibr28-1078155212449030"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cidon</surname><given-names>EU</given-names></name><name><surname>Centeno</surname><given-names>RG</given-names></name><name><surname>Lagarto</surname><given-names>EG</given-names></name><etal/></person-group>. <article-title>HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain</article-title>. <source>J Oncol</source> <year>2011</year>; <volume>2011</volume>: <fpage>391564</fpage>–<lpage>391564</lpage>. <comment>Epub 27 October 2011</comment>.</citation></ref>
<ref id="bibr29-1078155212449030"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients</article-title>. <source>J Clin Gastroenterol</source>. <comment>Epub ahead of print 4 November 2011</comment>.</citation></ref>
<ref id="bibr30-1078155212449030"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasprzyk</surname><given-names>PG</given-names></name><name><surname>Song</surname><given-names>SU</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name><etal/></person-group>. <article-title>Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies</article-title>. <source>Cancer Res</source> <year>1992</year>; <volume>52</volume>(<issue>10</issue>): <fpage>2771</fpage>–<lpage>2776</lpage>.</citation></ref>
<ref id="bibr31-1078155212449030"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto-Ouchi</surname><given-names>K</given-names></name><name><surname>Sekiguchi</surname><given-names>F</given-names></name><name><surname>Yasuno</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models</article-title>. <source>Cancer Chemother Pharmacol</source> <year>2007</year>; <volume>59</volume>(<issue>6</issue>): <fpage>795</fpage>–<lpage>805</lpage>.</citation></ref>
<ref id="bibr32-1078155212449030"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HP</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin</article-title>. <source>Int J Oncol</source> <year>2008</year>; <volume>32</volume>(<issue>1</issue>): <fpage>89</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr33-1078155212449030"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname><given-names>CE</given-names></name><name><surname>Forster</surname><given-names>J</given-names></name><name><surname>Lindquist</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Lapatinib plus capecitabine for HER2-positive advanced breast cancer</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>(<issue>26</issue>): <fpage>2733</fpage>–<lpage>2743</lpage>.</citation></ref>
<ref id="bibr34-1078155212449030"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Luber</surname><given-names>B</given-names></name><name><surname>Lorenzen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)</article-title>. <source>Br J Cancer</source> <year>2010</year>; <volume>102</volume>(<issue>3</issue>): <fpage>500</fpage>–<lpage>505</lpage>.</citation></ref>
<ref id="bibr35-1078155212449030"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract no. LBA4007]</article-title>. <source>J Clin Oncol</source> <year>2010</year>; <volume>28</volume>: <supplement>Suppl</supplement><fpage>18s</fpage>–<lpage>18s</lpage>.</citation></ref>
<ref id="bibr36-1078155212449030"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hudis</surname><given-names>CA</given-names></name></person-group>. <article-title>Trastuzumab—mechanism of action and use in clinical practice</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>(<issue>1</issue>): <fpage>39</fpage>–<lpage>51</lpage>.</citation></ref>
<ref id="bibr37-1078155212449030"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Leyland-Jones</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>(<issue>16</issue>): <fpage>1659</fpage>–<lpage>1672</lpage>.</citation></ref>
<ref id="bibr38-1078155212449030"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto-Ouchi</surname><given-names>K</given-names></name><name><surname>Sekiguchi</surname><given-names>F</given-names></name><name><surname>Yasuno</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models</article-title>. <source>Cancer Chemother Pharmacol</source> <year>2007</year>; <volume>59</volume>(<issue>6</issue>): <fpage>795</fpage>–<lpage>805</lpage>.</citation></ref>
<ref id="bibr39-1078155212449030"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romond</surname><given-names>EH</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>(<issue>16</issue>): <fpage>1673</fpage>–<lpage>1684</lpage>.</citation></ref>
<ref id="bibr40-1078155212449030"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><etal/></person-group>. <article-title>HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>(<issue>9555</issue>): <fpage>29</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr41-1078155212449030"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Leyland-Jones</surname><given-names>B</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</article-title>. <source>N Engl J Med</source> <year>2001</year>; <volume>344</volume>(<issue>11</issue>): <fpage>783</fpage>–<lpage>792</lpage>.</citation></ref>
<ref id="bibr42-1078155212449030"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>CL</given-names></name><name><surname>Cobleigh</surname><given-names>MA</given-names></name><name><surname>Tripathy</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</article-title>. <source>J Clin Oncol</source> <year>2002</year>; <volume>20</volume>(<issue>3</issue>): <fpage>719</fpage>–<lpage>726</lpage>.</citation></ref>
<ref id="bibr43-1078155212449030"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grávalos</surname><given-names>C</given-names></name><name><surname>Gómez-Martín</surname><given-names>C</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer</article-title>. <source>Clin Transl Oncol</source> <year>2011</year>; <volume>13</volume>(<issue>3</issue>): <fpage>179</fpage>–<lpage>184</lpage>.</citation></ref>
<ref id="bibr44-1078155212449030"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HP</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines</article-title>. <source>Cancer Lett</source> <year>2008</year>; <volume>272</volume>(<issue>2</issue>): <fpage>296</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr45-1078155212449030"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanizaki</surname><given-names>J</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Takezawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification</article-title>. <source>Mol Cancer Ther</source> <year>2010</year>; <volume>9</volume>(<issue>5</issue>): <fpage>1198</fpage>–<lpage>1207</lpage>.</citation></ref>
<ref id="bibr46-1078155212449030"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wainberg</surname><given-names>ZA</given-names></name><name><surname>Anghel</surname><given-names>A</given-names></name><name><surname>Desai</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo</article-title>. <source>Clin Cancer Res</source> <year>2010</year>; <volume>16</volume>(<issue>5</issue>): <fpage>1509</fpage>–<lpage>1519</lpage>.</citation></ref>
<ref id="bibr47-1078155212449030"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SF</given-names></name></person-group>. <article-title>Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer</article-title>. <source>Clin Ther</source> <year>2005</year>; <volume>27</volume>(<issue>6</issue>): <fpage>684</fpage>–<lpage>694</lpage>.</citation></ref>
<ref id="bibr48-1078155212449030"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Vega-Villegas</surname><given-names>ME</given-names></name><name><surname>Lopez-Brea</surname><given-names>MF</given-names></name></person-group>. <article-title>Cetuximab, its clinical use and future perspectives</article-title>. <source>Anticancer Drugs</source> <year>2008</year>; <volume>19</volume>(<issue>2</issue>): <fpage>99</fpage>–<lpage>113</lpage>.</citation></ref>
<ref id="bibr49-1078155212449030"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>W</given-names></name><name><surname>Hata</surname><given-names>J</given-names></name><name><surname>Yokozaki</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma</article-title>. <source>Int J Cancer</source> <year>1988</year>; <volume>41</volume>(<issue>2</issue>): <fpage>211</fpage>–<lpage>217</lpage>.</citation></ref>
<ref id="bibr50-1078155212449030"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safran</surname><given-names>H</given-names></name><name><surname>Suntharalingam</surname><given-names>M</given-names></name><name><surname>Dipetrillo</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity</article-title>. <source>Int J Radiat Oncol Biol Phys</source> <year>2008</year>; <volume>70</volume>(<issue>2</issue>): <fpage>391</fpage>–<lpage>395</lpage>.</citation></ref>
<ref id="bibr51-1078155212449030"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer</article-title>. <source>Invest New Drugs</source> <year>2011</year>; <volume>29</volume>(<issue>2</issue>): <fpage>366</fpage>–<lpage>373</lpage>.</citation></ref>
<ref id="bibr52-1078155212449030"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Di Fabio</surname><given-names>F</given-names></name><name><surname>Barone</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma (DOCETUX study)</article-title>. <source>Br J Cancer</source> <year>2009</year>; <volume>101</volume>(<issue>8</issue>): <fpage>1261</fpage>–<lpage>1268</lpage>.</citation></ref>
<ref id="bibr53-1078155212449030"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study</article-title>. <source>Ann Oncol</source> <year>2011</year>; <volume>22</volume>(<issue>6</issue>): <fpage>1358</fpage>–<lpage>1366</lpage>.</citation></ref>
<ref id="bibr54-1078155212449030"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JA</given-names></name><name><surname>Blaszkowsky</surname><given-names>LS</given-names></name><name><surname>Enzinger</surname><given-names>PC</given-names></name><etal/></person-group>. <article-title>A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma</article-title>. <source>Ann Oncol</source> <year>2011</year>; <volume>22</volume>(<issue>6</issue>): <fpage>1367</fpage>–<lpage>1373</lpage>.</citation></ref>
<ref id="bibr55-1078155212449030"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>MA</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study</article-title>. <source>J Clin Oncol</source> <year>2011</year>; <volume>29</volume>(<issue>30</issue>): <fpage>3968</fpage>–<lpage>3976</lpage>.</citation></ref>
<ref id="bibr56-1078155212449030"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Rayes</surname><given-names>BF</given-names></name><name><surname>Zalupski</surname><given-names>M</given-names></name><name><surname>Bekai-Saab</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers</article-title>. <source>Ann Oncol</source> <year>2010</year>; <volume>21</volume>(<issue>10</issue>): <fpage>1999</fpage>–<lpage>2004</lpage>.</citation></ref>
<ref id="bibr57-1078155212449030"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wainberg</surname><given-names>ZA</given-names></name><name><surname>Lin</surname><given-names>LS</given-names></name><name><surname>DiCarlo</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction</article-title>. <source>Br J Cancer</source> <year>2011</year>; <volume>105</volume>(<issue>6</issue>): <fpage>760</fpage>–<lpage>765</lpage>.</citation></ref>
<ref id="bibr58-1078155212449030"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Powell</surname><given-names>M</given-names></name><name><surname>O’Dwyer</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203</article-title>. <source>J Clin Oncol</source> <year>2010</year>; <volume>28</volume>(<issue>18</issue>): <fpage>2947</fpage>–<lpage>2951</lpage>.</citation></ref>
</ref-list>
</back>
</article>